

# VII CONGRESSO NAZIONALE B&M 2018

## IV SESSIONE

**Prof. Rocco Barazzoni**

*Professore associato di Medicina Interna,  
Università degli Studi di Trieste  
Segretario Generale Società ESPEN dal 2012 al 2016.*



**BRAIN AND  
MALNUTRITION**  
Chronic Diseases Association ONLUS





**NUTRIZIONE E NEURODEGENERAZIONE**

**MILANO**  
**10-11 MAGGIO 2018**

GRAND HOTEL VILLA TORRETTA  
Sesto San Giovanni

VII CONGRESSO NAZIONALE B&M  
SAVE THE DATE

**BRAIN AND MAENUTRITION**  
Chronic Diseases Association ONLUS

[www.bm-association.it](http://www.bm-association.it)



# Obesità e Sarcopenia

**Rocco Barazzoni**



Dept of Medical, Surgical and Health Sciences  
University of Trieste - Italy

## REPORT

# Sarcopenia: European consensus on definition and diagnosis

Report of the European Working Group on Sarcopenia in Older People  
Cruz-Jentoft et al, Age Ageing 2010



SARCOPENIA: a complex MULTIFACTORIAL Syndrome

## SENESCENCE

MOTONEURON

Satellite CELLS

DYSFUNCTION

## NUTRITION

ANOREXIA

MALABSORPTION

## MUSCLE DISUSE

IMMOBILITY

SEDENTARY Lifestyle



## ENDOCRINE

↓ SEX HORMONES

↓ VITAMIN D

↓ GH-IGF1

## METABOLISM

AGING

A PERFECT METABOLIC STORM

# AGING

## A PERFECT METABOLIC STORM

OX STRESS



INFLAMMATION

PROTEIN  
DEGRADATION





MASS  
FUNCTION

INSULIN  
RESISTANCE

+

+





## OVERWEIGHT and OBESITY

“Chronic conditions characterized by abnormal-excess fat accumulation leading to excess morbidity” (WHO)

Clinical = BMI > 30 kg/m<sup>2</sup>

# OBESITY per se

## A PERFECT MUSCLE METABOLIC STORM

OX STRESS



INFLAMMATION

PROTEIN  
DEGRADATION



MASS  
FUNCTION

INSULIN  
RESISTANCE

+



+

# COMPLICATED OBESITY

A PERFECT MUSCLE METABOLIC STORM

OX STRESS



INFLAMMATION

METABOLIC SYNDROME  
DIABETES

+



MASS

FUNCTION

+

INSULIN  
RESISTANCE



# ACUTE and CHRONIC DISEASE

## A PERFECT MUSCLE METABOLIC STORM

OX STRESS




INFLAMMATION



+

PROTEIN DEGRADATION



MASS


FUNCTION

+


INSULIN RESISTANCE

# THERAPEUTIC WEIGHT LOSS BARIATRIC SURGERY

-Deficiencies



## PROTEIN DEGRADATION




**MASS**  
**FUNCTION**

# Sarcopenic Obesity: The Confluence of Two Epidemics

Ronem Roubenoff

OBESITY RESEARCH Vol. 12 No. 6 June 2004 887



**AGING**

**OBESITY**

OR 1,74




**ABDOMINAL OBESITY**



OR 1,67

Garcia-Esquina et al, Obesity 2015

# Increased frailty in obese individuals with lower muscle mass




Baumgartner et al, Ob Res 2004


# Beyond BMI

## BODY COMPOSITION

Low Lean Mass and Lean Mass loss predict mortality in OBESE CANCER patients



Prado et al, Lancet Oncol 2008



Prado et al, Am J Clin Nutr 2013

**AWARENESS!!**

**Malnutrition!!**




THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

## ESPEN guidelines on definitions and terminology of clinical nutrition

T. Cederholm <sup>a,\*</sup>, R. Barazzoni <sup>b</sup>, P. Austin <sup>c,v</sup>, P. Ballmer <sup>d</sup>, G. Biolo <sup>e</sup>, S.C. Bischoff <sup>f</sup>, C. Compher <sup>g,1</sup>, I. Correia <sup>h,1</sup>, T. Higashiguchi <sup>i,1</sup>, M. Holst <sup>j</sup>, G.L. Jensen <sup>k,1</sup>, A. Malone <sup>l,1</sup>, M. Muscaritoli <sup>m</sup>, I. Nyulasi <sup>n,1</sup>, M. Pirlich <sup>o</sup>, E. Rothenberg <sup>p</sup>, K. Schindler <sup>q</sup>, S.M. Schneider <sup>r</sup>, M.A.E. de van der Schueren <sup>s,2</sup>, C. Sieber <sup>t</sup>, L. Valentini <sup>u</sup>, J.C. Yu <sup>v,1</sup>, A. Van Gossum <sup>w</sup>, P. Singer <sup>x</sup>


Clin Nutr 2016

Currently, there are no commonly accepted criteria for sarcopenic obesity beyond those for sarcopenia and obesity separately.



**MASS**

**FUNCTION**



Validity and Reliability of Tools to Measure Muscle Mass, Strength, and Physical Performance in Community-Dwelling Older People: A Systematic Review

Mijnarends et al, JAMDA 2013

**MUSCLE PERFORMANCE**

**MUSCLE STRENGTH**

**MUSCLE MASS**

BIA  
Single frequency  
Multifrequency<sup>7</sup>

BOD POD<sup>74</sup>  
Calf circumference  
CT<sup>13,17,83</sup>

DXA<sup>14-17,78-81</sup>  
Equation for LBV  
MRI<sup>17</sup>  
Skin-fold thickness<sup>33</sup>  
Ultrasonography<sup>13</sup>  
4-C model<sup>76,83</sup>

**SARCOPENIA**

**VARIABLE DEF**

**OBESITY**

**% Body Fat**

- **26-fold VARIATION** in SO prevalence
- **Elderly population**

Batsis et al, J Am Geriatr Soc 2013

Chest press<sup>27</sup>  
Dumbbell<sup>69</sup>  
Elastic bands<sup>69</sup>

Handheld dynamometer<sup>18-26</sup>

Manual muscle testing<sup>19</sup>  
Vigorimeter<sup>20</sup>

Plate with spring gauge<sup>28</sup>  
Pull down<sup>29</sup>

Continuous scaled physical functional performance<sup>30</sup>  
Figure-8 walk<sup>30</sup>  
Fullerton Functional Fitness Test battery<sup>47,\*</sup>  
Functional reach<sup>52,\*</sup>  
GAITrite mat (4.6 m mat with sensor)<sup>48,\*</sup>  
Gait speed (2 m to 1 km)<sup>31,36,37,40,42,43,48,53-55,\*</sup>

Speed (5 min)<sup>32,37,38,51,56,\*</sup>

Physical performance assessment tool-SF<sup>38,\*</sup>

Physical performance scale: chair rise, stair sit, kneel, supine rise<sup>44</sup>  
Physical capacity evaluation: walking speed, grip, etc.<sup>25,\*</sup>  
Physical performance test (em)<sup>57</sup>  
Physical performance test (em)<sup>33</sup>

Physical performance assessment tool-SF (physical function items)<sup>31</sup>  
Physical performance assessment tool-SF (physical function items)<sup>31</sup>

Sit to stand 5 times<sup>31,34,40,42,43,49</sup>

Sit to stand 10 times<sup>68</sup>

Sit to stand 30 sec<sup>41,45</sup>





THE EUROPEAN  
SOCIETY FOR  
CLINICAL  
NUTRITION AND  
METABOLISM

## ESPEN suggestion for diagnostic criteria for malnutrition

**Step 1. Risk screening by a validated instrument , e.g. NRS-2002, MUST, MNA(-SF), SNAQ, ...**

i.e. BMI, Weight loss, Reduced food intake, Disease severity

**Step 2. Diagnosis is confirmed by**

- **BMI  $<18.5 \text{ kg/m}^2$**

**or**

- **Weight loss  $>10\%$  (indefinite time)/ $>5\%$  last 3 mo** combined with either
- **BMI  $<20$  ( $<70 \text{ y}$ )/ $<22$  ( $>70 \text{ y}$ ) or**
- **FFMI  $<15$  and  $17 \text{ kg/m}^2$  in women and men, respect.**

# Global Leadership Initiative in Malnutrition

## Core committee

ASPEN: GL Jensen / C Compher  
ESPEN: T Cederholm / A Van Gossum  
FELANPE: I Correia / MC Gonzalez  
PENSA: R Fukushima / T Higashiguchi

## Working group


G Baptista, R Barazzoni, R Blaauw, A Crivelli, D Evans, L Gramlich, V Fuchs, S Jones, H Keller, A Malone, K Mogensen, M Muscaritoli, M Pirlich, V Pisprasert, M de van der Schueren, S Siltharm, P Singer, K Tappenden, D Waitzberg, NV Fuentes, L Lido, P Yamwong, J Yu, I Nyulasi



THE EUROPEAN  
SOCIETY FOR  
CLINICAL  
NUTRITION AND  
METABOLISM



American Society for Parenteral  
and Enteral Nutrition



# ALGORITHM FOR MALNUTRITION DIAGNOSIS

**Screening**



**Diagnosis**

**At risk for Malnutrition**

- Use validated screening tools



**Assessment Criteria**

- **Phenotype**
  - Weight loss
  - ↓BMI (underweight)
  - ↓ Muscle Mass
- **Etiology**
  - ↓ Food intake (or absorption)
  - ↑ Inflammation - Disease



**YES**

**AT LEAST**

- 1 Phenotype Criterion
- AND
- 1 Etiology Criterion

# Cut-Offs and SURROGATES: THE FINAL HURDLE?



## • ↓ MUSCLE MASS

E.G: fat free mass index (FFMI,  $\text{kg}/\text{m}^2$ ) by DEXA or BIA, CT, MRI.

Ethnicity adaptation NEEDED

ALTERNATIVES: when not available or by regional preference:

- physical exam
- standard anthropometric measures
- functional assessments (e.g. hand-grip strength) may be considered as a SUPPORTIVE measure.

\*\*Acute disease/injury-related with severe inflammation.

E.G: major infection, burns, trauma or closed head injury

\*\*\*Chronic disease-related with chronic or recurrent mild to moderate inflammation.

E.G.: malignant disease, COPD, CHF, CKD or any disease with chronic or recurrent Inflammation.

C-reactive protein may be used as a supportive laboratory measure.

# CLINICAL approach SARCOPENIC OBESITY



**OBESITY**

**COMPLICATIONS**

**COMORBIDITIES**

**+**

**THERAPEUTIC WEIGHT LOSS**

**BARIATRIC SURGERY**

**SARCOPENIC  
OBESITY**

**↓ OUTCOME**

**AGING  
CANCER  
CHRONIC DISEASE**



1000 - 1130	Joint Session with ESPEN - Sarcopenic Obesity: From Pathophysiology to Nutritional approach Chairs: R Schindler (Austria), R Vector (Italy)	Despachantes
1000 - 1030	Inflammation: the common ground?	L Poggiogalle (Italy)
1030 - 1100	Chronic disease, obesity and protein metabolism	Y Boirie (France)
1100 - 1130	Sarcopenic obesity: diagnosis and nutritional treatment	R Barazzoni (Italy)

# ESPEN-EASO Position paper

## Sarcopenic Obesity: Time to meet the challenge

Barazzoni et al, Clin Nutr in press 2018

**TREATMENT: multimodal approach**

**- NUTRITION**

**- EXERCISE (PA)**

**- HORMONAL - PHARMACOLOGICAL**

**LITTLE DATA FOCUSING on**

**OBESE-SARCOPENIC OBESE INDIVIDUALS!!**

**OBESITY!!**

**A PERFECT METABOLIC STORM**

**OX STRESS**



**INFLAMMATION**

**PROTEIN**

**ANABOLIC RESISTANCE**

**+**



**MASS**  
**FUNCTION**


**+**

**INSULIN  
RESISTANCE**



# NUTRITION QUANTITY

**PROTEIN  
DEGRADATION**




**MASS**

**FUNCTION**

**↑ PROTEIN ?**

Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study<sup>1-3</sup>



Taku et al, Am J Clin Nutr 2007

## INCREASING PROTEIN INTAKE

(gr / kg BW · day OR PERCENT energy/day)

- ↑ LEAN MASS
- ↓ SARCOPENIA
- ↑ PHYSICAL
- ↑ MUSCLE STRENGTH

Beasley et al, J Am Geriatr Soc 2013; Farsijani et al, Am J Clin Nutr 2016;  
Chorong et al, Nutrition 2016; Isanejad et al, Br J Nutr 2016

## PROTEIN DEGRADATION



**MASS**  
**FUNCTION**

# HEALTHY OLDER ADULTS

# CLINICAL NUTRITION



ESPEN endorsed recommendation

Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group

Nicolaas E.P. Deutz<sup>a,\*</sup>, Jürgen M. Bauer<sup>b</sup>, Rocco Barazzoni<sup>c</sup>, Gianni Biolo<sup>c</sup>, Yves Boirie<sup>d</sup>, Anja Bosy-Westphal<sup>e</sup>, Tommy Cederholm<sup>f,g</sup>, Alfonso Cruz-Jentoft<sup>h</sup>, Zeljko Krznarić<sup>i</sup>, K. Sreekumaran Nair<sup>j</sup>, Pierre Singer<sup>k</sup>, Daniel Teta<sup>l</sup>, Kevin Tipton<sup>m</sup>, Philip C. Calder<sup>n,o</sup>

Clin Nutr 2015

**1-1.2 g/kg · day**

## CHRONIC KIDNEY DISEASE

### HEMODIALYSIS – PERITONEAL DIALYSIS

ESPEN GLs: **1,2-1,4 g/kg BW**

Cano et al, Clin Nutr 2009

# LOW-CALORIE DIET

Study or Subgroup	High Protein			Standard Protein			Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI
	Mean	SD	Total	Mean	SD	Total			
<b>≥ 12 Weeks</b>									
Belobrajdic 2010 (27)	-1.9	3	34	-3.1	4.3	42	3.6%	1.20 [-0.45, 2.85]	
Campbell 2010 (28)	-1.6	1.1	13	-2.2	1.6	15	7.4%	0.60 [-0.41, 1.61]	
Evangelista 2009 (30)	0.6	1	5	-0.3	0.3	5	8.3%	0.90 [-0.02, 1.82]	
Farnsworth 2003 - F (11)	-0.1	1.4	21	-1.5	1.4	22	9.2%	1.40 [0.56, 2.24]	
Farnsworth 2003 - M (11)	-2.5	7.4	7	-1.9	5.6	7	0.2%	-0.60 [-7.47, 6.27]	
<b>Subtotal (95% CI)</b>			<b>278</b>			<b>291</b>	<b>68.6%</b>	<b>0.61 [0.20, 1.02]</b>	

Intervention for MUSCLE maintenance

Traylor 2006 (42)	-2.78	4.11	44	-4.00	11.14	41	0.5%	1.26 [-2.34, 4.30]
Wycherley 2010 (43)	-1.9	1.5	12	-2.2	1.9	16	5.4%	0.30 [-0.96, 1.56]
<b>Subtotal (95% CI)</b>			<b>72</b>			<b>73</b>	<b>31.4%</b>	<b>0.03 [-0.58, 0.64]</b>

<b>&lt; 12 Weeks</b>									
Baba 1999 (12)	-1.2	1.1	7	-0.5	1.3	8	4.4%	1.36 [-2.33, 0.65]	
Johnston 2004 (32)	-2.1	1.3	9	-1.74	1.12	7	5.9%	-0.36 [-1.55, 0.83]	
Kasim-Karakas 2009 (33)	-0.3	1.3	11	-0.6	1.1	13	7.7%	0.30 [-0.67, 1.27]	
Layman 2003 (9)	-0.88	1.14	12	-1.21	2.01	12	5.1%	0.33 [-0.98, 1.64]	
Parker 2002 (24)	-0.61	1.87	26	-1.4	2.88	28	5.3%	0.79 [-0.50, 2.08]	
Torbay 2002 (41)	-0.2	2.1	7	-0.7	1.3	7	3.0%	0.50 [-1.33, 2.33]	
<b>Subtotal (95% CI)</b>			<b>72</b>			<b>73</b>	<b>31.4%</b>	<b>0.03 [-0.58, 0.64]</b>	

<b>Total (95% CI)</b>			<b>350</b>			<b>364</b>	<b>100.0%</b>	<b>0.43 [0.09, 0.78]</b>
-----------------------	--	--	------------	--	--	------------	---------------	--------------------------

↑ PROTEIN

FIGURE 5. Meta-analysis for changes in fat-free mass (kg) in randomized controlled trials that compared high-protein, low-fat diets with isocalorically prescribed standard-protein, low-fat, energy-restricted diets. IV, inverse variance.



## OBESITY + DISEASE

# GUIDELINES INTENSIVE CARE (ASPEN)

## NUTRITIONAL SUPPORT

**PROTEIN**: Very High-Protein

BMI < 40: 2 g/kg IBW

BMI > 40: 2.5 g/kg IBW

McClave et al, JPEN 2016



## OBESITY + DISEASE

# GUIDELINES INTENSIVE CARE (ASPEN)

## NUTRITIONAL SUPPORT

### CALORIE

- DO NOT OVERFEED
- PROVIDE ADEQUATE CALORIES
- PREVENT METABOLIC COMPLICATIONS



### **PERMISSIVE UNDERFEEDING (65-70%)**

BMI < 50: 11-14 kcal/kg actual BW

BMI > 50: 22-25 kcal/kg IBW

McClave et al, JPEN 2016

# «GENERAL» OBESITY GUIDELINES ?

## **2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults**

**A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society**



- 3b. Prescribe a calorie-restricted diet, for obese and overweight individuals who would benefit from weight loss, based on the patient's preferences and health status, and preferably refer to a nutrition professional\* for counseling. A variety of dietary approaches can produce weight loss in overweight and obese adults, as presented in CQ3, ES2. A (Strong)
- Higher-protein diet (25% of total calories from protein, 30% of total calories from fat, and 45% of total calories from carbohydrate), with provision of foods that realize an energy deficit.
  - Higher-protein Zone™-type diet (5 meals/d, each with 40% of total calories from carbohydrate, 30% of total calories from protein, and 30% of total calories from fat) without formal prescribed energy restriction but with a realized energy deficit.

# SARCOPENIC OBESITY

IF SEEKING WEIGHT LOSS :

-Preserve MUSCLE MASS  
(↑protein, exercise)

Improved Function With Enhanced Protein Intake per Meal: A Pilot Study of Weight Reduction in Frail, Obese Older Adults Porter Starr et al, J Gerontol Med Sci 2016





# High-Protein Diet

## SAFETY - FEASIBILITY

# Protein and Chronic Kidney Disease



		Change in Estimated GFR	
Protein Intake Quart	Participants with Normal Renal Function (n = 1135)‡	Participants with Mild Renal Insufficiency (n = 489)§	
	<i>mL/min per 1.73 m<sup>2</sup></i>		
	0 (referent)	0 (referent)	
	2.45 (-0.98 to 5.88)	-2.51 (-6.25 to 1.23)	
	1.82 (-1.77 to 5.41)	-0.10 (-4.06 to 3.86)	
	2.23 (-1.66 to 6.12)	-0.32 (-4.50 to 3.86)	
	0.46 (-3.83 to 4.75)	-4.77 (-9.52 to -0.02)	

Knight et al, Ann Int Med 2003

Higher Protein intake NOT indicated in elderly individuals if GFR<30


Bauer et al, JAMDA 2013



**OBESITY ?**

# Protein and Chronic Metabolic Complications

## Excess Plasma AMINO ACIDS predict INSULIN RESISTANCE and DIABETES



RISK-BENEFIT  
evaluation  
(statins)


Guasch-Ferre et al, Diabetes Care 2016

### Protein Ingestion Induces Muscle Insulin Resistance Independent of Leucine-Mediated mTOR Activation

Smith et al, Diabetes 2015





# Protein QUALITY

## Animal/Vegetable



**DIAAS** Digestible Indispensable AA Score


# Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study<sup>1-3</sup>



Taku et al, Am J Clin Nutr 2007


# Influences on Food Choices

100 gr MEAT: 25-30 gr Protein  
 100 gr DAIRY: 20-25  
 100 gr FISH: 15-18  
 100 gr LEGUMES: 30-40 (Dry!)







**Eating PATTERNS**


**Knowledge**  
**Cost-Access**  
**Convenience**




# NUTRITION QUALITY



+





Eur J Nutr. 2017 Mar 16. doi: 10.1007/s00394-017-1422-2. Association of the Baltic Sea and Mediterranean diets with indices of sarcopenia in elderly women, OSPTRE-FPS study. Isanejad M1,2, Sirola J3,4, Mursu J5, Rikkinen T3, Kröger H3,4, Tuppurainen M6, Erkkilä AT5.

## Measurements of skeletal muscle mass and power are positively related to a Mediterranean dietary pattern in women

Kelaiditis et al, Osteoporosis Int 2016

**Table 2** Measures of muscle mass, muscle strength, and inflammation by quartile of Mediterranean diet score in 2570 females aged 18–79 years

	Model	Q1	Q2	Q3	Q4	Q4-Q1	P trend
Mediterranean diet score (points)	–	0–3	4	5	6–9	–	–
Fat-free mass (%)	n=	897	538	461	674	–	–
	1	60.9 ± 0.3	60.6 ± 0.3	61.3 ± 0.3	61.6 ± 0.3	0.7 ± 0.4	0.021
	2	60.7 ± 0.2	60.6 ± 0.3	61.6 ± 0.3	61.6 ± 0.2	0.9 ± 0.3	<0.001
	3	60.7 ± 0.2	60.6 ± 0.3	61.6 ± 0.3	61.7 ± 0.2	1.0 ± 0.3	<0.001
Fat-free mass index (kg/m <sup>2</sup> )	n=	897	538	461	674	–	–
	1	14.9 ± 0.1	15.0 ± 0.1	15.2 ± 0.1	15.1 ± 0.1	0.1 ± 0.1	0.050
	2	15.0 ± 0.1	15.0 ± 0.1	15.1 ± 0.1	15.1 ± 0.1	0.1 ± 0.1	0.076
	3	15.0 ± 0.1	15.0 ± 0.1	15.1 ± 0.1	15.1 ± 0.1	0.1 ± 0.1	0.086
Grip strength <sup>a</sup> (kg)	n=	303	214	188	244	–	–
	1	28.6 ± 0.4	28.2 ± 0.5	28.8 ± 0.4	29.4 ± 0.4	0.8 ± 0.5	0.470
	2	28.9 ± 0.3	28.6 ± 0.4	28.8 ± 0.4	28.7 ± 0.3	–0.1 ± 0.5	0.855
	3	28.8 ± 0.3	28.6 ± 0.4	28.8 ± 0.4	28.7 ± 0.3	–0.1 ± 0.5	0.855
Arm muscle quality <sup>a</sup> (kg/kg)	n=	303	214	188	244	–	–
	1	13.3 ± 0.2	13.1 ± 0.2	13.6 ± 0.2	13.7 ± 0.2	0.4 ± 0.2	0.077
	2	13.4 ± 0.1	13.2 ± 0.2	13.5 ± 0.2	13.5 ± 0.2	0.1 ± 0.2	0.472
	3	13.4 ± 0.1	13.2 ± 0.2	13.5 ± 0.2	13.5 ± 0.2	0.1 ± 0.2	0.472
Leg explosive power <sup>b</sup> (watts/kg)	n=	662	410	340	502	–	–
	1	87.4 ± 1.5	90.3 ± 1.8	92.6 ± 2.0	94.7 ± 1.8	7.3 ± 2.3	0.001
	2	86.8 ± 1.4	90.8 ± 1.8	92.5 ± 1.9	95.0 ± 1.7	8.2 ± 2.2	<0.001
	3	86.8 ± 1.4	90.7 ± 1.8	92.7 ± 1.9	95.1 ± 1.7	8.3 ± 2.2	<0.001
C-reactive protein <sup>c</sup> (mg/L)	n=	497	359	315	487	–	–
	1	1.6 (1.5, 1.8)	1.6 (1.4, 1.8)	1.6 (1.5, 1.8)	1.6 (1.4, 1.7)	–	0.644
	2	1.6 (1.5, 1.8)	1.6 (1.4, 1.7)	1.6 (1.5, 1.8)	1.6 (1.5, 1.7)	–	0.879
	3	1.6 (1.5, 1.8)	1.6 (1.4, 1.7)	1.6 (1.4, 1.8)	1.6 (1.5, 1.7)	–	0.842



# **NUTRACEUTICALS**

**overcome-reduce anabolic resistance!**


**ANABOLIC SUBSTRATES**

**ANTIINFLAMMATORY**




**ANTIOXIDANTS**

# ESSENTIAL AMINO ACIDS and METABOLITES (Leucine: HYDROXY-METHYL BUTYRATE)

↑ Prot SYNTHESIS



↓ Prot DEGRADATION



**AGING**

Deutz et al, Clin Nutr 2013

Berton et al, PLoS One 2015

# VITAMIN D

## **Vitamin D Deficiency-Induced Muscle Wasting Occurs through the Ubiquitin Proteasome Pathway and Is Partially Corrected by Calcium in Male Rats**

Mehrajuddin Bhat, Ramesh Kalam, Syed SYH Qadri , Seshacharyulu Madabushi, and Ayesha Ismail

Endocrinology 2013

## Vitamin D deficiency down-regulates Notch pathway contributing to skeletal muscle atrophy in old wistar rats

Carla Domingues-Faria<sup>1,2,4</sup>, Audrey Chanet<sup>2,4</sup>, Jérôme Salles<sup>2,4</sup>, Alexandre Berry<sup>2,4</sup>, Christophe Giraudet<sup>2,4</sup>, Véronique Patrac<sup>2,4</sup>, Philippe Denis<sup>3,4</sup>, Katia Bouton<sup>2,4</sup>, Nicolas Goncalves-Mendes<sup>1</sup>, Marie-Paule Vasson<sup>1,5</sup>, Yves Boirie<sup>2,6</sup> and Stéphane Walrand<sup>2,4\*</sup>

Nutr Metab 2014

# COMBINED SUPPLEMENTATIONS

A high whey protein-, leucine-, and vitamin D-enriched supplement preserves muscle mass during intentional weight loss in obese older adults: a double-blind randomized controlled trial<sup>1-3</sup>


Verreijen et al, AJCN 2015

Whey protein, amino acids, and vitamin D supplementation with physical activity increases fat-free mass and strength, functionality, and quality of life and decreases inflammation in sarcopenic elderly<sup>1,2</sup>


Rondanelli et al, Am J Clin Nutr 2016

- «FAST» protein
- Essential-BCAA
- Hydroxy-Methyl-Butirate (HMB)
- Vitamin D

↑ EFFECTIVENESS



# NUTRACEUTICALS



**NO STRONG DATA FOCUSING on  
OBESE-SARCOPENIC OBESE  
INDIVIDUALS!!**



# Conclusions

- 1) SARCOPENIC OBESITY is potentially a major clinical and prognostic feature in the heterogeneous and growing obese patient population;
- 2) A large body of work is needed to increase AWARENESS and improve its clinical DEFINITION;
- 3) Nutrition should be a therapeutic cornerstone both in prevention and treatment of low muscle mass and function; quality of DIETARY PATTERNS and adequate PROTEIN INTAKE appear to be key nutritional tools;
- 4) A number of nutritional-nutraceutical supplements could play beneficial therapeutic roles including ESSENTIAL and BC AMINO ACIDS, N-3 PUFA, VITAMIN D and ANTIOXIDANTS;
- 5) A large effort in high-quality CLINICAL RESEARCH will be mandatory to define optimal nutritional treatment tools in obese and sarcopenic obese individuals

Thank you for  
your  
attention

